B Group, Inc.
An institutional investment manager in DALLAS, TX. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2043476.
- Reported value$213.0m
- Positions19
Holdings: 19 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Invesco QQQ TR | PUT | 46090E953 | 36.8 | 17.3% | 50,000 | Put | New+50,000 |
| Adma Biologics IncADMA | COM | 000899104 | 27.3 | 12.8% | 3,262,542 | Added+55,000 | |
| Palisade Bio IncPALI | COM | 696389402 | 23.9 | 11.2% | 11,414,285 | Unchanged | |
| NRX Pharmaceuticals IncNRXP | COM NEW | 629444209 | 16.7 | 7.9% | 4,091,767 | Added+1,091,767 | |
| Faeth Therapeutics IncFTH | COM NEW | 81728A207 | 15.3 | 7.2% | 610,169 | New+610,169 | |
| Taysha Gene Therapies IncTSHA | COM SHS | 877619106 | 12.3 | 5.8% | 1,800,556 | Unchanged | |
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 11.1 | 5.2% | 33,237 | Unchanged | |
| Cellectis S aCLLS | SPON ADS | 15117K103 | 9.8 | 4.6% | 3,281,501 | Unchanged | |
| ZAI Lab LtdZLAB | ADR | 98887Q104 | 8.6 | 4.0% | 450,646 | Unchanged | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 7.5 | 3.5% | 140,000 | Added+12,500 | |
| Oruka Therapeutics IncORKA | COM | 687604108 | 7.1 | 3.4% | 75,000 | Unchanged | |
| Iovance Biotherapeutics IncIOVA | COM | 462260100 | 6.2 | 2.9% | 1,500,000 | Unchanged | |
| Spyre Therapeutics IncSYRE | COM NEW | 00773J202 | 6.2 | 2.9% | 70,000 | Reduced−30,000 | |
| Aura Biosciences IncAURA | COM | 05153U107 | 5.4 | 2.5% | 764,243 | Added+166,667 | |
| Assembly Biosciences IncASMB | COM NEW | 045396207 | 4.8 | 2.3% | 175,706 | Unchanged | |
| Bright Minds Biosciences IncDRUG | COM NEW | 10919W405 | 4.7 | 2.2% | 67,500 | Unchanged | |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 4.5 | 2.1% | 135,000 | Unchanged | |
| Sight Sciences IncSGHT | COM | 82657M105 | 3.7 | 1.7% | 970,000 | Unchanged | |
| Foghorn Therapeutics IncFHTX | COM | 344174107 | 1.0 | 0.5% | 200,000 | Added+98,000 |
Sold out: 3 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | COM | 03770N101 | 0.0 | 0.0% | 0 | Sold out−7,500 | |
| Replimune Group IncREPL | COM | 76029N106 | 0.0 | 0.0% | 0 | Sold out−26,000 | |
| Soleno Therapeutics Inc | COM | 834203309 | 0.0 | 0.0% | 0 | Sold out−7,500 |
Source: SEC EDGAR, Form 13F-HR, accession 0001420506-26-001657 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.